Mereo Biopharma Group PLC
NASDAQ:MREO
Mereo Biopharma Group PLC
NASDAQ:MREO
Price:
3.01 USD
-2.9%
Market Closed
Updated:
May 8, 2024
Mereo Biopharma Group PLC
Income from Continuing Operations
|
Mereo Biopharma Group PLC
Income from Continuing Operations Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Mereo Biopharma Group PLC
NASDAQ:MREO
|
Income from Continuing Operations
-£34.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Income from Continuing Operations
-$151.1m
|
CAGR 3-Years
-142%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Income from Continuing Operations
-$208.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Income from Continuing Operations
-$168.2m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Income from Continuing Operations
-£55.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Income from Continuing Operations
£30.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
See Also
What is Mereo Biopharma Group PLC's Income from Continuing Operations?
Income from Continuing Operations
-34.2m
GBP
-34.2m
GBP
Based on the financial report for Dec 31, 2022, Mereo Biopharma Group PLC's Income from Continuing Operations amounts to -34.2m GBP.
What is Mereo Biopharma Group PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
1%
1%
The average annual Income from Continuing Operations growth rates for Mereo Biopharma Group PLC have been 1% over the past three years .
You don't have any saved screeners yet
